With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

HealthDay News — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with the risk of developing nonarteritic anterior ischemic optic ...

In a pooled analysis of three randomized trials, CPAP had overall null cardiovascular effects in patients with obstructive ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

A new study has found that the average woman tries to lose weight seven times over their lifespan – but fails six times.

Rajesh Kumar, HSBC's head of life sciences and healthcare research, discusses the key concerns facing anti-obesity drug ...